You are here: Industry Insights > amyloidosis

News List

Subtle Cognitive Difficulties May Predict Amyloidosis drugs
January 02, 2020
Individuals with objectively-defined subtle cognitive difficulties (Obj-SCD) have faster amyloid accumulation and faster entorhinal cortical thinning compared with ...
Amyloidosis treatment discontinued from clinical trials europeanpharmaceuticalreview
June 11, 2019
A treatment for amyloidosis has been pulled from clinical trials after failing to reach endpoints.
AHA News: Potentially Fatal Buildup of Proteins in the Heart Often Goes Undiagnosed drugs
May 22, 2019
AHA News: Potentially Fatal Buildup of Proteins in the Heart Often Goes Undiagnosed.
FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis worldpharmanews
May 07, 2019
On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults.
Pfizer eyes ATTR cardiomyopathy filing for tafamidis after acing phase 3 trial fiercebiotech
August 28, 2018
Analysts suggest the drug could reach the market in 2019
Alnylam’s novel RNA therapy Onpattro wins nod for hATTR amyloidosis pharmatimes
August 14, 2018
The US Food and Drug Administration has approved Alnylam’s RNAi therapeutic Onpattro for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.